Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.
Journal of affective disorders January 15, 2025 Sara Ellis, Catherine Bostian, Wendy Feng et al. 23 citations
In a small, uncontrolled trial, 15 veterans with severe treatment-resistant depression received a single 25 mg dose of psilocybin. At three weeks, 60% met criteria for response and 53% for remission. By twelve weeks, 47% maintained response and 40% remission. Co-occurring PTSD did not affect outcomes, and the intensity of the psychedelic experience did not correlate with depression improvement. Four participants who needed to restart antidepressants were counted as non-responders from that point. No unexpected adverse events occurred. The authors note limitations including the small sample and lack of a control group, and call for further study.